U.S. Markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
10,586.00+6.00 (+0.06%)
At close: 05:57PM GMT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10,580.00
Bid10,410.00 x 0
Ask10,800.00 x 0
Day's Range10,540.00 - 10,626.00
52 Week Range8,250.00 - 11,886.00
Avg. Volume2,132,716
Market Cap169.01B
Beta (5Y Monthly)0.16
PE Ratio (TTM)48.56
EPS (TTM)218.00
Earnings DateNov 10, 2022
Forward Dividend & Yield2.22 (2.21%)
Ex-Dividend DateAug 11, 2022
1y Target Est117.23
  • Zacks

    AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

    Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

  • MarketWatch

    AstraZeneca says Forxiga approved in EU for heart failure

    AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.

  • Reuters

    PRESS DIGEST-British Business - Feb 6

    The following are the top stories on the business pages of British newspapers. The Times - The UK is losing out on investment from AstraZeneca Plc to more competitive countries, Tom Keith-Roach, the head of the company, warned. - A British semiconductor company, IQE Plc could move overseas unless the government sets out its strategy for the sector in the next six months, its chief executive said.